Genelux Corporation
NASDAQ:GNLXBiotechnology
+$0.08 today
- Market cap
- $107.66M
- Beta
- 0.55
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.98
Volume 0.80M
Average 0.19M
GNLX Total Liabilities
Everything the company owes to creditors and other parties.
Genelux CorporationNASDAQ: GNLX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 3.4% from a year ago
Total liabilities stood at $9.45M at the end of Q1 FY2026, up 3.4% from a year earlier and up 26.3% from the prior quarter. Over 3 fiscal years it compounded at -43.4% a year.
Context
- Total liabilities amounted to 29.2% of total assets at the end of Q1 FY2026, up 5.8 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +3.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 7.48M USD
- Year-over-year change
- -11.4%
- 4-year CAGR
- -34.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.48M | -11.4% |
| FY2024 | 2024-12-31 | 8.44M | +0.3% |
| FY2023 | 2023-12-31 | 8.42M | -79.6% |
| FY2022 | 2022-12-31 | 41.31M | +0.2% |
| FY2021 | 2021-12-31 | 41.24M | — |
Total Liabilities vs competitors
How GNLX compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +3.4% is the 3rd highest of 11, against a peer median of -16.9%.
- Total liabilities amounts to 29.2% of total assets for GNLX, versus a peer median of 33.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $229.27M USD | -7.5% | +22.5% | 79.3% | |
| Mar 2026 | CHF 105.89M CHF | -8.9% | +86.2% | 77.1% | |
| Mar 2026 | $76.96M USD | -17.5% | -4.2% | 21.9% | |
| Mar 2026 | $65.72M USD | -77.9% | -6.8% | 57.1% | |
| Mar 2026 | $63.89M USD | +200.9% | +33.5% | 31.6% | |
| Mar 2026 | $39.42M USD | +60.2% | +26.7% | 36.2% | |
| Mar 2026 | $24.33M USD | -17.8% | -2.8% | 36.6% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $18.86M USD | -49.8% | -52.8% | 7.5% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $11.31M USD | -16.2% | +11.3% | 4.3% |
GNLXGenelux Corporation | Mar 2026 | $9.45M USD | +3.4% | -43.4% | 29.2% |
| Mar 2026 | $6.56M USD | -20.4% | -42.3% | 16.2% | |
| Peer median (excluding GNLX) | — | -16.9% | +4.2% | 33.9% | |
Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.5M | 397K | 9.42M | 8.57M | 5.33M |
| Short-term Investments | 0 | 0 | 13.77M | 22.33M | 9.26M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.33M | 1.5M | 1.01M | 653K | 535K |
| Total Current Assets | 5.82M | 1.89M | 24.2M | 31.55M | 15.13M |
| Property, Plant & Equipment (Net) | 2.21M | 1.98M | 3.6M | 3.08M | 3.75M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 92K | 1.66M | 92K | 92K | 144K |
| Total Non-current Assets | 2.3M | 3.64M | 3.69M | 3.17M | 3.9M |
| Total Assets | 8.13M | 5.53M | 27.89M | 34.72M | 19.03M |
| Account Payables | 4.46M | 6.78M | 3.78M | 5.57M | 4.36M |
| Short-term Debt | 6.16M | 16.4M | 653K | 329K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 4.5M | 170K | 0 | 0 | 0 |
| Other Current Liabilities | 4.11M | 5.16M | 0 | 0 | 0 |
| Total Current Liabilities | 22.48M | 31.63M | 6.55M | 6.9M | 6.23M |
| Long-term Debt | 18.02M | 8.52M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 18.75M | 9.69M | 1.87M | 1.54M | 1.26M |
| Total Liabilities | 41.24M | 41.31M | 8.42M | 8.44M | 7.48M |
| Common Stock | 9K | 9K | 27K | 35K | 38K |
| Retained Earnings | (184.58M) | (189.78M) | (221.52M) | (251.39M) | (283.54M) |
| Accumulated OCI | 2K | 2K | 14K | 64K | 9K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (33.11M) | (35.78M) | 19.47M | 26.27M | 11.54M |
| Total Debt | 25.31M | 26.35M | 2.52M | 1.87M | 1.69M |
| Net Debt | 20.82M | 25.96M | (6.9M) | (6.7M) | (3.65M) |
Genelux Corporation
NASDAQ:GNLX
Intrinsic Alpha fair value
Locked
Current Price
$2.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.